This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01400/identifier/chemspider/
n25http://linked.opendata.cz/resource/AHFS/
n23http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01400/identifier/chebi/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01400/identifier/wikipedia/
n26http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB01400/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01400/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n27http://www.rxlist.com/cgi/generic/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01400/identifier/pubchem-compound/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01400/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01400/identifier/drugbank/
n11http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB01400/identifier/national-drug-code-directory/
n21http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01400
rdf:type
n3:Drug
n3:description
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. [PubChem]
n3:dosage
n22:271B4651-363D-11E5-9242-09173F13E4C5 n22:271B4652-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
The half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes.
n3:indication
Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
owl:sameAs
n14:DB01400 n26:DB01400
dcterms:title
Neostigmine
adms:identifier
n6:Neostigmine n8:76014-002 n9:4456 n12:46509161 n15:C07258 n16:PA450611 n17:DB01400 n18:7514 n19:4301
n3:mechanismOfAction
Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. The drug inhibits acetylcholinesterase which is responsible for the degredation of acetylcholine. So, with acetylcholinesterase inhibited, more acetylcholine is present By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both nicotinic and muscarinic receptors which are involved in muscle contraction.. It does not cross the blood-brain barrier.
n3:packager
n23:271B4649-363D-11E5-9242-09173F13E4C5 n23:271B464A-363D-11E5-9242-09173F13E4C5 n23:271B4647-363D-11E5-9242-09173F13E4C5 n23:271B4648-363D-11E5-9242-09173F13E4C5
n3:synonym
m-Trimethylammoniumphenyldimethylcarbamate Eustigmin (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate Vagostigmine Prostigmine 3-Trimethylammoniumphenyl N,N-dimethylcarbamate Eustigmine
n3:toxicity
Overdosage of Neostigmine can cause cholinergic crisis, which is characterized by increasing muscle weakness, and through involvement of the muscles of respiration, may result in death. The LD 50 of neostigmine methylsulfate in mice is 0.3 ± 0.02 mg/kg intravenously, 0.54 ± 0.03 mg/kg subcutaneously, and 0.395 ± 0.025 mg/kg intramuscularly; in rats the LD 50 is 0.315 ± 0.019 mg/kg intravenously, 0.445 ± 0.032 mg/kg subcutaneously, and 0.423 ± 0.032 mg/kg intramuscularly.
n20:hasAHFSCode
n25:12-04-00
n3:proteinBinding
Protein binding to human serum albumin ranges from 15 to 25 percent.
n3:salt
foaf:page
n11:neostigmine.html n27:neostigmine.htm
n3:IUPAC-Name
n4:271B4657-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B465D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B465C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4659-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B465A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B465B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4655-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4653-363D-11E5-9242-09173F13E4C5 n4:271B4656-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4654-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n21:N07AA01 n21:S01EB06
n3:H-Bond-Acceptor-Count
n4:271B4663-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4664-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B465E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B465F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4661-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4660-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4662-363D-11E5-9242-09173F13E4C5
n3:absorption
Neostigmine bromide is poorly absorbed from the gastrointestinal tract following oral administration
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
59-99-4
n3:containedIn
n7:271B464B-363D-11E5-9242-09173F13E4C5 n7:271B464C-363D-11E5-9242-09173F13E4C5 n7:271B464F-363D-11E5-9242-09173F13E4C5 n7:271B4650-363D-11E5-9242-09173F13E4C5 n7:271B464D-363D-11E5-9242-09173F13E4C5 n7:271B464E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4667-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4669-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B466A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4666-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4665-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4668-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4658-363D-11E5-9242-09173F13E4C5